Clinical Trials Logo

Aortic Valve Insufficiency clinical trials

View clinical trials related to Aortic Valve Insufficiency.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06381271 Recruiting - Clinical trials for Aortic Valve Regurgitation

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

Start date: October 30, 2018
Phase:
Study type: Observational

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected

NCT ID: NCT06295068 Recruiting - Clinical trials for Aortic Valve Insufficiency

Evaluation of ARi With OpSens SavvyWire

ARi
Start date: November 30, 2023
Phase:
Study type: Observational

The goal of this observational study is to establish the degree of agreement to Aortic Regurgitation (AR) severity during aortic valve intervention between the Aortic Regurgitation Index (ARi) measured by the Opsens SavvyWire, Echography and Aortography in subjects with severe aortic stenosis (AS) undergoing echo guided valve intervention. The main question it aims to answer is how the ARi measured with the Opsens SavvyWire compared with regurgitation evaluation derived by Echography and Aortography.

NCT ID: NCT06235385 Recruiting - Clinical trials for Aortic Valve Stenosis

European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study

EACVI-MMVD
Start date: February 7, 2024
Phase:
Study type: Observational

This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.

NCT ID: NCT06101888 Recruiting - Clinical trials for Aortic Regurgitation

Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the safety and effectiveness of the TaurusTrio™ Heart Valve System in a patient population with symptomatic severe AR requiring replacement/repair of their native aortic valve that are at high risk for open surgical aortic valve replacement/repair (SAVR).

NCT ID: NCT06034028 Recruiting - Clinical trials for Aortic Valve Disease

J-Valve TF Early Feasibility Study

JVTF EFS
Start date: October 16, 2023
Phase: N/A
Study type: Interventional

The main objective of this study is to assess the preliminary safety and effectiveness of the J-Valve TF System in patients with symptomatic severe native aortic regurgitation who are judged by a multi-disciplinary heart team to be eligible for the device and to be at high risk for open surgical aortic valve replacement.

NCT ID: NCT05902897 Recruiting - Clinical trials for Aortic Valve Stenosis

Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

Start date: January 1, 2023
Phase:
Study type: Observational

Collect data on the safety and clinical performance of the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

NCT ID: NCT05895487 Recruiting - Clinical trials for Mitral Valve Insufficiency and Aortic Valve Insufficiency

Study on Efficacy, Safety and Durability of the UniLine Prosthesis in the Treatment of Aortic and Mitral Valve Disease

Start date: November 1, 2022
Phase:
Study type: Observational

Acquired heart diseases continue to remain one of the most common causes of cardiac mortality and morbidity. In the Russian Federation, open surgery treatment of acquired valvular heart diseases (AVHD) is performed in more than 40 regions by specialists from 92 healthcare organizations. Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique. The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis. In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions. Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity. The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Local Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.

NCT ID: NCT05892588 Recruiting - Clinical trials for Aortic Valve Stenosis

Prevalence Study of Cardiovascular Diseases in a Population ≥ 65 Years in Italy

PREVASC
Start date: June 1, 2022
Phase:
Study type: Observational [Patient Registry]

This registry is a large-scale epidemiological study (PREVASC) aimed at estimating the prevalence of symptomatic and asymptomatic valvular hear disease in men and women aged over 65 years randomly selected in Italy.

NCT ID: NCT05799573 Recruiting - Clinical trials for Aortic Valve Regurgitation

CT Scan Sizing for Perceval Sutureless Valve

PERCEVAL
Start date: December 1, 2022
Phase:
Study type: Observational

The Perceval sutureless aortic bioprosthesis is a bovine pericardium valve mounted in a nitinol stent that can be compressed and positioned in a valve delivery system. Similarly, to transcatheter aortic valve implantation (TAVI) devices, the anchoring and good sealing of the Perceval bioprosthesis relies on oversizing by design of the nitinol stent compared with the native aortic annulus. With the advent of TAVI, cardiac computed tomography (CT) has become the gold standard technique for measuring the aortic annulus in patients undergoing transcatheter procedures, and the CT-derived axial image of the aortic virtual basal ring (VBR) is considered as the reference for sizing by most of the manufacturers of transcatheter valves . Interestingly, the VBR lies exactly on the plane passing through the nadir of the 3 aortic cusps, that is where, according to the instructions for use, a correctly positioned Perceval valve should be deployed. VBR could then provide a good estimate of the annular dimension for the Perceval pre-operative sizing.

NCT ID: NCT05737264 Recruiting - Clinical trials for Transcatheter Aortic Valve Replacement

TAVR in Adults With Pure Severe Aortic Regurgitation

SENSE-AR
Start date: December 1, 2022
Phase:
Study type: Observational

The study aimed to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with severe native valve aortic insufficiency. It is a multicentre, observational cohort study. The primary endpoint consisted of a composite of all-cause death, disabling stroke, or rehospitalization for heart failure at 12 months postoperatively. According to previous research results and opinions of expert groups, the sample size was expected to be 76 cases.